Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 262

1.

Cooperative Effect of Oncogenic MET and PIK3CA in an HGF-Dominant Environment in Breast Cancer.

Liu S, Li S, Wang B, Liu W, Gagea M, Chen H, Sohn J, Parinyanitikul N, Primeau T, Do KA, Vande Woude GF, Mendelsohn J, Ueno NT, Mills GB, Tripathy D, Gonzalez-Angulo AM.

Mol Cancer Ther. 2019 Feb;18(2):399-412. doi: 10.1158/1535-7163.MCT-18-0710. Epub 2018 Dec 5.

PMID:
30518672
2.

Differential responses of MET activations to MET kinase inhibitor and neutralizing antibody.

Kou J, Musich PR, Staal B, Kang L, Qin Y, Yao ZQ, Zhang B, Wu W, Tam A, Huang A, Hao HX, Vande Woude GF, Xie Q.

J Transl Med. 2018 Sep 12;16(1):253. doi: 10.1186/s12967-018-1628-y.

3.

MET4 expression predicts poor prognosis of gastric cancers with Helicobacter pylori infection.

Sakamoto N, Tsujimoto H, Takahata R, Cao B, Zhao P, Ito N, Shimazaki H, Ichikura T, Hase K, Vande Woude GF, Shinomiya N.

Cancer Sci. 2017 Mar;108(3):322-330. doi: 10.1111/cas.13146.

4.

Chromosome instability drives phenotypic switching to metastasis.

Gao C, Su Y, Koeman J, Haak E, Dykema K, Essenberg C, Hudson E, Petillo D, Khoo SK, Vande Woude GF.

Proc Natl Acad Sci U S A. 2016 Dec 20;113(51):14793-14798. doi: 10.1073/pnas.1618215113. Epub 2016 Dec 5.

5.

Genomic profiling of a Hepatocyte growth factor-dependent signature for MET-targeted therapy in glioblastoma.

Johnson J, Ascierto ML, Mittal S, Newsome D, Kang L, Briggs M, Tanner K, Marincola FM, Berens ME, Vande Woude GF, Xie Q.

J Transl Med. 2015 Sep 17;13:306. doi: 10.1186/s12967-015-0667-x.

6.

Cartilage-specific deletion of Mig-6 results in osteoarthritis-like disorder with excessive articular chondrocyte proliferation.

Staal B, Williams BO, Beier F, Vande Woude GF, Zhang YW.

Proc Natl Acad Sci U S A. 2014 Feb 18;111(7):2590-5. doi: 10.1073/pnas.1400744111. Epub 2014 Feb 3.

7.

Overexpression of HGF Promotes HBV-Induced Hepatocellular Carcinoma Progression and Is an Effective Indicator for Met-Targeting Therapy.

Xie Q, Su Y, Dykema K, Johnson J, Koeman J, De Giorgi V, Huang A, Schlegel R, Essenburg C, Kang L, Iwaya K, Seki S, Khoo SK, Zhang B, Buonaguro F, Marincola FM, Furge K, Vande Woude GF, Shinomiya N.

Genes Cancer. 2013 Jul;4(7-8):247-60. doi: 10.1177/1947601913501075.

8.

Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent.

Merchant M, Ma X, Maun HR, Zheng Z, Peng J, Romero M, Huang A, Yang NY, Nishimura M, Greve J, Santell L, Zhang YW, Su Y, Kaufman DW, Billeci KL, Mai E, Moffat B, Lim A, Duenas ET, Phillips HS, Xiang H, Young JC, Vande Woude GF, Dennis MS, Reilly DE, Schwall RH, Starovasnik MA, Lazarus RA, Yansura DG.

Proc Natl Acad Sci U S A. 2013 Aug 6;110(32):E2987-96. doi: 10.1073/pnas.1302725110. Epub 2013 Jul 23.

9.

MET and ERBB2 are coexpressed in ERBB2+ breast cancer and contribute to innate resistance.

Paulson AK, Linklater ES, Berghuis BD, App CA, Oostendorp LD, Paulson JE, Pettinga JE, Melnik MK, Vande Woude GF, Graveel CR.

Mol Cancer Res. 2013 Sep;11(9):1112-21. doi: 10.1158/1541-7786.MCR-13-0042. Epub 2013 Jul 3.

10.

MET: a critical player in tumorigenesis and therapeutic target.

Graveel CR, Tolbert D, Vande Woude GF.

Cold Spring Harb Perspect Biol. 2013 Jul 1;5(7). pii: a009209. doi: 10.1101/cshperspect.a009209. Review.

11.

Strengthening context-dependent anticancer effects on non-small cell lung carcinoma by inhibition of both MET and EGFR.

Zhang YW, Staal B, Essenburg C, Lewis S, Kaufman D, Vande Woude GF.

Mol Cancer Ther. 2013 Aug;12(8):1429-41. doi: 10.1158/1535-7163.MCT-13-0016. Epub 2013 May 29.

12.

RTK inhibition: looking for the right pathways toward a miracle.

Xie Q, Vande Woude GF, Berens ME.

Future Oncol. 2012 Nov;8(11):1397-400. doi: 10.2217/fon.12.130.

PMID:
23148613
13.

Cancer-type regulation of MIG-6 expression by inhibitors of methylation and histone deacetylation.

Zhang YW, Staal B, Dykema KJ, Furge KA, Vande Woude GF.

PLoS One. 2012;7(6):e38955. doi: 10.1371/journal.pone.0038955. Epub 2012 Jun 12.

14.

Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma.

Xie Q, Bradley R, Kang L, Koeman J, Ascierto ML, Worschech A, De Giorgi V, Wang E, Kefene L, Su Y, Essenburg C, Kaufman DW, DeKoning T, Enter MA, O'Rourke TJ, Marincola FM, Vande Woude GF.

Proc Natl Acad Sci U S A. 2012 Jan 10;109(2):570-5. doi: 10.1073/pnas.1119059109. Epub 2011 Dec 27.

15.

Benzoquinone ansamycin 17AAG binds to mitochondrial voltage-dependent anion channel and inhibits cell invasion.

Xie Q, Wondergem R, Shen Y, Cavey G, Ke J, Thompson R, Bradley R, Daugherty-Holtrop J, Xu Y, Chen E, Omar H, Rosen N, Wenkert D, Xu HE, Vande Woude GF.

Proc Natl Acad Sci U S A. 2011 Mar 8;108(10):4105-10. doi: 10.1073/pnas.1015181108. Epub 2011 Feb 22. Erratum in: Proc Natl Acad Sci U S A. 2011 Mar 29;108(13):5472. Daughtery-Holtrop, Jennifer [corrected to Daugherty-Holtrop, Jennifer].

16.

Germline met mutations in mice reveal mutation- and background-associated differences in tumor profiles.

Graveel CR, DeGroot JD, Sigler RE, Vande Woude GF.

PLoS One. 2010 Oct 25;5(10):e13586. doi: 10.1371/journal.pone.0013586.

17.

RhoA and RhoC are both required for the ROCK II-dependent promotion of centrosome duplication.

Kanai M, Crowe MS, Zheng Y, Vande Woude GF, Fukasawa K.

Oncogene. 2010 Nov 11;29(45):6040-50. doi: 10.1038/onc.2010.328. Epub 2010 Aug 9.

18.

Phase II trial to evaluate gemcitabine and etoposide for locally advanced or metastatic pancreatic cancer.

Melnik MK, Webb CP, Richardson PJ, Luttenton CR, Campbell AD, Monroe TJ, O'Rourke TJ, Yost KJ, Szczepanek CM, Bassett MR, Truszkowski KJ, Stein P, Van Brocklin MW, Davis AT, Bedolla G, Vande Woude GF, Koo HM.

Mol Cancer Ther. 2010 Aug;9(8):2423-9. doi: 10.1158/1535-7163.MCT-09-0854. Epub 2010 Aug 3.

19.

MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth.

Zhang YW, Staal B, Essenburg C, Su Y, Kang L, West R, Kaufman D, Dekoning T, Eagleson B, Buchanan SG, Vande Woude GF.

Cancer Res. 2010 Sep 1;70(17):6880-90. doi: 10.1158/0008-5472.CAN-10-0898. Epub 2010 Jul 19. Erratum in: Cancer Res. 2011 Apr 1;71(7):2804.

20.

Therapeutic potential of hepatocyte growth factor/scatter factor neutralizing antibodies: inhibition of tumor growth in both autocrine and paracrine hepatocyte growth factor/scatter factor:c-Met-driven models of leiomyosarcoma.

Gao CF, Xie Q, Zhang YW, Su Y, Zhao P, Cao B, Furge K, Sun J, Rex K, Osgood T, Coxon A, Burgess TL, Vande Woude GF.

Mol Cancer Ther. 2009 Oct;8(10):2803-10. doi: 10.1158/1535-7163.MCT-09-0125.

21.

The decline in U.S. cancer mortality in people born since 1925.

Kort EJ, Paneth N, Vande Woude GF.

Cancer Res. 2009 Aug 15;69(16):6500-5. doi: 10.1158/0008-5472.CAN-09-0357.

22.

Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer.

Graveel CR, DeGroot JD, Su Y, Koeman J, Dykema K, Leung S, Snider J, Davies SR, Swiatek PJ, Cottingham S, Watson MA, Ellis MJ, Sigler RE, Furge KA, Vande Woude GF.

Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12909-14. doi: 10.1073/pnas.0810403106. Epub 2009 Jun 30.

23.

Mig-6 modulates uterine steroid hormone responsiveness and exhibits altered expression in endometrial disease.

Jeong JW, Lee HS, Lee KY, White LD, Broaddus RR, Zhang YW, Vande Woude GF, Giudice LC, Young SL, Lessey BA, Tsai SY, Lydon JP, DeMayo FJ.

Proc Natl Acad Sci U S A. 2009 May 26;106(21):8677-82. doi: 10.1073/pnas.0903632106. Epub 2009 May 13.

24.

Met amplification and tumor progression in Cdkn2a-deficient melanocytes.

Vanbrocklin MW, Robinson JP, Whitwam T, Guilbeault AR, Koeman J, Swiatek PJ, Vande Woude GF, Khoury JD, Holmen SL.

Pigment Cell Melanoma Res. 2009 Aug;22(4):454-60. doi: 10.1111/j.1755-148X.2009.00576.x. Epub 2009 Apr 29.

25.

Novel therapeutic inhibitors of the c-Met signaling pathway in cancer.

Eder JP, Vande Woude GF, Boerner SA, LoRusso PM.

Clin Cancer Res. 2009 Apr 1;15(7):2207-14. doi: 10.1158/1078-0432.CCR-08-1306. Epub 2009 Mar 24. Review.

26.

A highly invasive human glioblastoma pre-clinical model for testing therapeutics.

Xie Q, Thompson R, Hardy K, DeCamp L, Berghuis B, Sigler R, Knudsen B, Cottingham S, Zhao P, Dykema K, Cao B, Resau J, Hay R, Vande Woude GF.

J Transl Med. 2008 Dec 3;6:77. doi: 10.1186/1479-5876-6-77.

27.

Advances in Cancer Research: Centennial Volume. Introduction.

Klein G, Vande Woude GF.

Adv Cancer Res. 2008;100:v-vii. doi: 10.1016/S0065-230X(08)00008-0. No abstract available.

PMID:
18620090
28.

Identification of a met-binding peptide from a phage display library.

Zhao P, Grabinski T, Gao C, Skinner RS, Giambernardi T, Su Y, Hudson E, Resau J, Gross M, Vande Woude GF, Hay R, Cao B.

Clin Cancer Res. 2007 Oct 15;13(20):6049-55.

29.

Differential expression of c-Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissue.

Lindemann K, Resau J, Nährig J, Kort E, Leeser B, Annecke K, Welk A, Schäfer J, Vande Woude GF, Lengyel E, Harbeck N.

Histopathology. 2007 Jul;51(1):54-62.

PMID:
17593080
30.

Chromosome instability, chromosome transcriptome, and clonal evolution of tumor cell populations.

Gao C, Furge K, Koeman J, Dykema K, Su Y, Cutler ML, Werts A, Haak P, Vande Woude GF.

Proc Natl Acad Sci U S A. 2007 May 22;104(21):8995-9000. Epub 2007 May 15.

31.

Mig-6, signal transduction, stress response and cancer.

Zhang YW, Vande Woude GF.

Cell Cycle. 2007 Mar 1;6(5):507-13. Epub 2007 Mar 31. Review.

PMID:
17351343
32.

c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion.

Sawada K, Radjabi AR, Shinomiya N, Kistner E, Kenny H, Becker AR, Turkyilmaz MA, Salgia R, Yamada SD, Vande Woude GF, Tretiakova MS, Lengyel E.

Cancer Res. 2007 Feb 15;67(4):1670-9.

33.

An alternatively spliced form of Met receptor is tumorigenic.

Lee JH, Gao CF, Lee CC, Kim MD, Vande Woude GF.

Exp Mol Med. 2006 Oct 31;38(5):565-73.

PMID:
17079873
34.

Evidence that MIG-6 is a tumor-suppressor gene.

Zhang YW, Staal B, Su Y, Swiatek P, Zhao P, Cao B, Resau J, Sigler R, Bronson R, Vande Woude GF.

Oncogene. 2007 Jan 11;26(2):269-76. Epub 2006 Jul 3.

PMID:
16819504
35.

In vivo direct molecular imaging of early tumorigenesis and malignant progression induced by transgenic expression of GFP-Met.

Moshitch-Moshkovitz S, Tsarfaty G, Kaufman DW, Stein GY, Shichrur K, Solomon E, Sigler RH, Resau JH, Vande Woude GF, Tsarfaty I.

Neoplasia. 2006 May;8(5):353-63.

36.

HGF/SF increases tumor blood volume: a novel tool for the in vivo functional molecular imaging of Met.

Tsarfaty G, Stein GY, Moshitch-Moshkovitz S, Kaufman DW, Cao B, Resau JH, Vande Woude GF, Tsarfaty I.

Neoplasia. 2006 May;8(5):344-52.

37.

Structural basis of hepatocyte growth factor/scatter factor and MET signalling.

Gherardi E, Sandin S, Petoukhov MV, Finch J, Youles ME, Ofverstedt LG, Miguel RN, Blundell TL, Vande Woude GF, Skoglund U, Svergun DI.

Proc Natl Acad Sci U S A. 2006 Mar 14;103(11):4046-51. Epub 2006 Mar 6.

38.

Antibody microarray profiling reveals individual and combined serum proteins associated with pancreatic cancer.

Orchekowski R, Hamelinck D, Li L, Gliwa E, vanBrocklin M, Marrero JA, Vande Woude GF, Feng Z, Brand R, Haab BB.

Cancer Res. 2005 Dec 1;65(23):11193-202.

39.

Nuclear imaging of Met-expressing human and canine cancer xenografts with radiolabeled monoclonal antibodies (MetSeek).

Hay RV, Cao B, Skinner RS, Su Y, Zhao P, Gustafson MF, Qian CN, Teh BT, Knudsen BS, Resau JH, Shen S, Waters DJ, Gross MD, Vande Woude GF.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7064s-7069s.

40.

Targeted disruption of Mig-6 in the mouse genome leads to early onset degenerative joint disease.

Zhang YW, Su Y, Lanning N, Swiatek PJ, Bronson RT, Sigler R, Martin RW, Vande Woude GF.

Proc Natl Acad Sci U S A. 2005 Aug 16;102(33):11740-5. Epub 2005 Aug 8.

41.

Proliferation and invasion: plasticity in tumor cells.

Gao CF, Xie Q, Su YL, Koeman J, Khoo SK, Gustafson M, Knudsen BS, Hay R, Shinomiya N, Vande Woude GF.

Proc Natl Acad Sci U S A. 2005 Jul 26;102(30):10528-33. Epub 2005 Jul 15.

42.

Geldanamycins exquisitely inhibit HGF/SF-mediated tumor cell invasion.

Xie Q, Gao CF, Shinomiya N, Sausville E, Hay R, Gustafson M, Shen Y, Wenkert D, Vande Woude GF.

Oncogene. 2005 May 26;24(23):3697-707.

PMID:
15782129
43.

A mouse model of activating Met mutations.

Graveel CR, London CA, Vande Woude GF.

Cell Cycle. 2005 Apr;4(4):518-20. Epub 2005 Apr 7. Review.

PMID:
15738649
44.

HGF/SF-Met signaling in tumor progression.

Gao CF, Vande Woude GF.

Cell Res. 2005 Jan;15(1):49-51. Review.

45.

The distinct stage-specific effects of 2-(p-amylcinnamoyl)amino-4-chlorobenzoic acid on the activation of MAP kinase and Cdc2 kinase in Xenopus oocyte maturation.

Islam A, Sakamoto Y, Kosaka K, Yoshitome S, Sugimoto I, Yamada K, Shibuya E, Vande Woude GF, Hashimoto E.

Cell Signal. 2005 Apr;17(4):507-23.

PMID:
15601628
46.

Enhanced growth of human met-expressing xenografts in a new strain of immunocompromised mice transgenic for human hepatocyte growth factor/scatter factor.

Zhang YW, Su Y, Lanning N, Gustafson M, Shinomiya N, Zhao P, Cao B, Tsarfaty G, Wang LM, Hay R, Vande Woude GF.

Oncogene. 2005 Jan 6;24(1):101-6.

PMID:
15531925
47.

RNA interference reveals that ligand-independent met activity is required for tumor cell signaling and survival.

Shinomiya N, Gao CF, Xie Q, Gustafson M, Waters DJ, Zhang YW, Vande Woude GF.

Cancer Res. 2004 Nov 1;64(21):7962-70.

48.

C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu.

Lengyel E, Prechtel D, Resau JH, Gauger K, Welk A, Lindemann K, Salanti G, Richter T, Knudsen B, Vande Woude GF, Harbeck N.

Int J Cancer. 2005 Feb 10;113(4):678-82.

49.

Met decoys: will cancer take the bait?

Zhang YW, Graveel C, Shinomiya N, Vande Woude GF.

Cancer Cell. 2004 Jul;6(1):5-6.

50.

Reanalysis of cancer drugs: old drugs, new tricks.

Vande Woude GF, Kelloff GJ, Ruddon RW, Koo HM, Sigman CC, Barrett JC, Day RW, Dicker AP, Kerbel RS, Parkinson DR, Slichenmyer WJ.

Clin Cancer Res. 2004 Jun 1;10(11):3897-907. Review. No abstract available.

Supplemental Content

Loading ...
Support Center